Non-Small Cell Lung Cancer Clinical Trial Pipeline | 100+ Companies Pioneering the Future of Treatment

Major pharmaceutical companies are working to advance the pipeline space and unlock the future growth potential of the Non-Small Cell Lung Cancer treatment landscape.

DelveInsight's 'Non-Small Cell Lung Cancer Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Non-Small Cell Lung Cancer therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Non-Small Cell Lung Cancer pipeline domain.

For Non-Small Cell Lung Cancer emerging drugs, the Non-Small Cell Lung Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Non-Small Cell Lung Cancer Pipeline Report
• DelveInsight's Non-Small Cell Lung Cancer Pipeline analysis depicts a robust space with 100+ active players working to develop 120+ pipeline drugs for Non-Small Cell Lung Cancer treatment.

• The leading Non-Small Cell Lung Cancer companies include Bayer, Zai Lab, Amgen, Mirati Therapeutics, GSK, AstraZeneca, Novartis, Sanofi, Merck, Bristol-Myers Squibb, ImmunoGen, Boehringer Ingelheim, Tesaro, Phanes Therapeutics, Genentech, Seattle Genetics, Boehringer Ingelheim, Ono Pharmaceutical, Pfizer, BeiGene, Acuitas Therapeutics, PDS Biotech, Cantargia, Elevar Therapeutics, Nuvectis Pharma, Mersana Therapeutics, Gilead Sciences, Transgene, Immutep, Biontech, LianBio, Exelixis, BerGenBio, Immunovant, Galecto, Iovance Biotherapeutics, Trizell Inc., Heat Biologics, Greenwich LifeSciences, Altimmune, Molecular Partners, and Cantex Pharmaceuticals, and others are evaluating their lead assets to improve the Non-Small Cell Lung Cancer treatment landscape.

• Key Non-Small Cell Lung Cancer pipeline therapies in various stages of development include Firmonertinib, Belrestotug, Sacituzumab Tirumotecan, Trodelvy, Pyrotinib, Ociperlimab, Volrustomig, Gotistobart, Ivonescimab, Zynyz, Zejula, Savolitinib, Divarasib, Tiragolumab, Rilvegostomig, Jemperli, Serplulimab, MK-1084, Opdualag, Tedopi, Domvanalimab, Sigvotatug Vedotin, Ceralasertib, Zipalertinib, Anktiva, Ameile, Telisotuzumab Vedotin, Datopotamab Deruxtecan, Zongertinib, Bay 2927088, MRNA-4157, Patritumab Deruxtecan, Olomorasib, Plinabulin + Docetaxel, Eftilagimod Alpha, Acasunlimab, Sunvozertinib, Fianlimab, Cobolimab, Livmoniplimab, Dovbleron, Amtagvi, BNT327, Can-2409, Mecbotamab Vedotin, Bemcentinib, IO102-IO103, IBI363, Vebreltinib, LP-300, Sotevtamab, Avutometinib, FF-10832, Naptumomab Estafenatox, BNT116, Vepafestinib, EP0031, Pamvatamig, Dupert, Reqorsa, Zidesamtinib, NVL-520, NVL-655, PDC*Lung01, Tas3351, Sabestomig, Selvigaltin, Jin-A02, Sasanlimab, and others.

• In January 2025, the US Food and Drug Administration (FDA) granted priority review to Dizal's new drug application (NDA) for Sunvozertinib, targeting the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients.

• In December 2024, Nuvation Bio Inc. announced that the FDA has accepted its New Drug Application (NDA) for taletrectinib. This investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) is being evaluated for the treatment of advanced ROS1+ non-small cell lung cancer (NSCLC), irrespective of treatment line.

• In December 2024, Merus N.V. announced that the FDA approved BIZENGRI® (zenocutuzumab-zbco), the first and only treatment for adults with advanced unresectable or metastatic pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion, who have experienced disease progression after prior systemic therapy.

• In November 2024, AstraZeneca and Daiichi Sankyo announced the submission of a new biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for datopotamab deruxtecan (Dato-DXd) as a treatment for non-small cell lung cancer (NSCLC).

• In October 2024, Bristol Myers Squibb announced that the FDA has approved Opdivo (nivolumab) for the treatment of adult patients with resectable non-small cell lung cancer (NSCLC) without EGFR mutations or ALK rearrangements.

• In September 2024, AstraZeneca's Tagrisso (osimertinib) received U.S. approval for treating adult patients with unresectable Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who have not experienced disease progression during or after platinum-based chemoradiation therapy.

• In September 2024, Johnson & Johnson announced that the FDA has approved RYBREVANT (amivantamab-vmjw) in combination with standard chemotherapy (carboplatin and pemetrexed) for adult patients with locally advanced or metastatic non-small cell lung cancer featuring epidermal growth factor receptor exon 19 deletions or L858R substitution mutations, following disease progression on an EGFR tyrosine kinase inhibitor.

• In September 2024, AstraZeneca and Daiichi Sankyo announced that the TROPION-Lung01 Phase III trial for datopotamab deruxtecan (Dato-DXd) showed a clinically meaningful trend toward improved overall survival compared to docetaxel in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).

Request a sample and discover the recent breakthroughs happening in the Non-Small Cell Lung Cancer pipeline landscape @ https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Non-Small Cell Lung Cancer Overview
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, originating in the lung tissues. It grows more slowly compared to small cell lung cancer (SCLC), but it often spreads to other parts of the body by the time it is diagnosed. This makes early detection and treatment crucial for improving outcomes. While small cell lung cancer is characterized by small, round cells under the microscope and tends to grow quickly, non-small cell lung cancer features larger cells and generally has a slower growth rate. However, NSCLC is frequently diagnosed after it has spread, emphasizing the importance of early intervention.

Lung cancer is a significant health concern, with approximately 230,000 diagnoses made annually in the United States and around 135,000 deaths per year. This results in more deaths than prostate, breast, brain, and colorectal cancers combined. It is the leading cause of cancer death in men and the second most common in women. Fortunately, this statistic is gradually declining due to anti-smoking campaigns and a decrease in tobacco use. Lung cancer classification follows the 2015 World Health Organization (WHO) guidelines, which use immunohistochemistry and light microscopy to help guide treatment decisions and assess the prognosis.

Non-small cell lung cancer (NSCLC) is a broad category that includes several subtypes, with adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma being the most common. Adenocarcinoma is the most prevalent type, accounting for about half of all lung cancer cases. Squamous cell carcinoma was once the most frequently diagnosed type but is now found more often in the periphery of the lung. Large cell carcinoma is a diagnosis of exclusion and is poorly differentiated, making it difficult to classify further using immunohistochemistry (IHC) or electron microscopy. The etiology of NSCLC includes both avoidable and unavoidable risk factors, with tobacco use being the most well-known avoidable cause. Other risk factors include alcohol use, secondhand smoke exposure, and environmental pollutants such as asbestos, radon, arsenic, chromium, and nickel, along with ionizing radiation and polycyclic aromatic hydrocarbons.

Find out more about Non-Small Cell Lung Cancer medication @ https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Non-Small Cell Lung Cancer Treatment Analysis: Drug Profile
V940: Merck Sharp & Dohme LLC
V940 is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient's tumor. It is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed and produced based on the unique mutational signature of the DNA sequence of the patient's tumor. Upon administration into the body, the algorithmically derived and RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity. The drug is in Phase III stage for the treatment of NSCLC.

QL1706: Qilu Pharmaceutical Co., Ltd.
QL1706 is an investigational bifunctional antibody with additional anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibody could increase the anti-tumor effect of anti-programmed cell death 1 (PD-1) antibody. QL1706 is a novel dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA4 IgG1 antibodies produced by a single cell line. The drug is in Phase III stage for the treatment of NSCLC.

Zenocutuzumab (MCLA-128): Merus N.V.
Zenocutuzumab (MCLA-128; Zeno) is a Biclonics antibody that overcomes HER3 mediated NRG1 (or NRG1 fusion) signaling in tumor cells. Zeno docks on HER2, then binds to and blocks the NRG1 fusion-HER3 interaction and HER3 heterodimerization with HER2. It has a dual mechanism against cancer, as it prevents NRG1 fusions from binding to the protein HER3 and it blocks the interaction of HER3 with HER2, which the cancer cells depend on to survive and multiply. Currently, the drug is in Phase II stage for the treatment of NSCLC.

Key Non-Small Cell Lung Cancer Therapies and Companies
• Firmonertinib: Arrivent Biopharma
• Belrestotug (Eos-448) + JEMPERLI (Dostarlimab): Iteos Therapeutics And GSK
• Sacituzumab Tirumotecan (MK-2870): Merck And Kelun-Biotech
• Trodelvy (Sacituzumab Govitecan): Gilead Sciences
• Pyrotinib: Jiangsu Hengrui Medicine
• Ociperlimab (BGB-A1217): BieGene
• Volrustomig (Medi5752): AstraZeneca
• Gotistobart (BNT316): OncoC4/BioNTech
• Ivonescimab (AK112): Akeso Biopharma/Summit Therapeutics
• Zynyz (Retifanlimab-DLWR): Incyte/Macrogenics
• Zejula (Niraparib): GlaxoSmithKline
• Savolitinib: AstraZeneca/Hutchison Medipharma
• Divarasib (GDC-6036): Hoffmann-La Roche/Genentech
vTiragolumab (RG6058): Hoffmann-La Roche
• Rilvegostomig (AZD2936): AstraZeneca
• JEMPERLI (Dostarlimab): GlaxoSmithKline And AnaptysBio
• Serplulimab (HLX10): Shanghai Henlius Biotech
• MK-1084: Otsuka Pharmaceutical
• Opdualag (Nivolumab And Relatlimab): Bristol-Myers Squibb
• Tedopi: OSE Immunotherapeutics
• Domvanalimab: Arcus Biosciences And Gilead Sciences
• Sigvotatug Vedotin (PF08046047/SGN-B6A): Pfizer
• Ceralasertib (AZD6738): AstraZeneca
• Zipalertinib (CLN-081): Cullinan Oncology/Taiho Pharma
• Anktiva (N-803, Nogapendekin Alfa Inbakicept-PMLN): ImmunityBio
• Ameile (Aumolertinib,Almonertinib,Hs-10206): Jiangsu Hansoh Pharmaceutical
• Telisotuzumab Vedotin (AbbV-399, Teliso-V): AbbVie
• Datopotamab Deruxtecan: Daiichi Sankyo/AstraZeneca
• Zongertinib (BI-1810631): Boehringer Ingelheim
• Bay 2927088: Bayer
• MRNA-4157 (V940): Moderna Therapeutics/Merck Sharp & Dohme
• Patritumab Deruxtecan: Daiichi Sankyo/AstraZeneca
• Olomorasib (LY3537982): Eli Lilly And Company
• Plinabulin + Docetaxel: BeyondSpring
• Eftilagimod Alpha (Efti, Imp321): Immutep
• Acasunlimab (BNT311): Genmab
• Sunvozertinib (DZD9008): Dizal Pharmaceutical
• Fianlimab (REGN3767): Regeneron Pharmaceuticals
• Cobolimab: GlaxoSmithKline
• Livmoniplimab (ARGX-115): AbbVie
• Dovbleron (Taletrectinib): NuVation Bio/Innovent Biologics/Daiichi Sankyo/Nippon Kayaku
• Amtagvi (LN-145): Iovance Biotherapeutics
• BNT327 (PM8002): BioTheus/BioNTech
• Can-2409 (Aglatimagene Besadenovec): Candel Therapeutics
• Mecbotamab Vedotin (BA3011, CAB-AXL-ADC): BioAtla
• Bemcentinib: BergenBio/Rigel Pharmaceuticals
• IO102-IO103: IO Biotech
• IBI363: Innovent Biologics
• Vebreltinib (APL-101): ApolloMics
• LP-300: Lantern Pharma
• Sotevtamab (AB-16B5): Alethia Biotherapeutics
• Avutometinib (VS-6766): Verastem Oncology
• FF-10832: Fujifilm Corporation
• Naptumomab Estafenatox (NAP): Neotx Therapeutics/ Active Biotech
• BNT116: BioNTech SE/Regeneron Pharmaceuticals
• Vepafestinib (TAS0953/HM06): Taiho Pharmaceutical And Helsinn Healthcare
• EP0031 (A400): Ellipses Pharma/Kelun-Biotech
• Pamvatamig (MCLA-129): Merus
• Dupert (Fulzerasib): Genfleet Therapeutics
• Reqorsa (Quaratusugene Ozeplasmid): Genprex
• Zidesamtinib (NVL-520): Nuvalent
• NVL-655: Nuvalent
• PDCLung01: PDCLine Pharma
• Tas3351: Taiho Oncology
• Sabestomig (AZD7789): AstraZeneca
• Selvigaltin (GB1211): Galecto Biotech
• Jin-A02: J Ints Bio
• Sasanlimab: Pfizer

Learn more about the novel and emerging Non-Small Cell Lung Cancer pipeline therapies @ https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Non-Small Cell Lung Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Non-Small Cell Lung Cancer Pipeline Report
• Coverage: Global
• Key Non-Small Cell Lung Cancer Companies: Bayer, Zai Lab, Amgen, Mirati Therapeutics, GSK, AstraZeneca, Novartis, Sanofi, Merck, Bristol-Myers Squibb, ImmunoGen, Boehringer Ingelheim, Tesaro, Phanes Therapeutics, Genentech, Seattle Genetics, Boehringer Ingelheim, Ono Pharmaceutical, Pfizer, BeiGene, Acuitas Therapeutics, PDS Biotech, Cantargia, Elevar Therapeutics, Nuvectis Pharma, Mersana Therapeutics, Gilead Sciences, Transgene, Immutep, Biontech, LianBio, Exelixis, BerGenBio, Immunovant, Galecto, Iovance Biotherapeutics, Trizell Inc., Heat Biologics, Greenwich LifeSciences, Altimmune, Molecular Partners, and Cantex Pharmaceuticals, and others.
• Key Non-Small Cell Lung Cancer Pipeline Therapies: Bayer, Zai Lab, Amgen, Mirati Therapeutics, GSK, AstraZeneca, Novartis, Sanofi, Merck, Bristol-Myers Squibb, ImmunoGen, Boehringer Ingelheim, Tesaro, Phanes Therapeutics, Genentech, Seattle Genetics, Boehringer Ingelheim, Ono Pharmaceutical, Pfizer, BeiGene, Acuitas Therapeutics, PDS Biotech, Cantargia, Elevar Therapeutics, Nuvectis Pharma, Mersana Therapeutics, Gilead Sciences, Transgene, Immutep, Biontech, LianBio, Exelixis, BerGenBio, Immunovant, Galecto, Iovance Biotherapeutics, Trizell Inc., Heat Biologics, Greenwich LifeSciences, Altimmune, Molecular Partners, and Cantex Pharmaceuticals, and others.

Dive deep into rich insights for drugs used for Non-Small Cell Lung Cancer treatment; visit @ https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Non-Small Cell Lung Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Non-Small Cell Lung Cancer Pipeline Therapeutics
6. Non-Small Cell Lung Cancer Pipeline: Late-Stage Products (Phase III)
7. Non-Small Cell Lung Cancer Pipeline: Late-Stage Products (Phase III)
8. Non-Small Cell Lung Cancer Pipeline: Mid-Stage Products (Phase II)
9. Non-Small Cell Lung Cancer Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.